SCHEMBL15922286

SCHEMBL15922286

C=CCOc1ccc(C)cc1C(=O)Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.55
TSHR P16473 1/20 0.55
LIG1 P18858 1/20 0.49
KDM4E B2RXH2 3/20 0.45
FLT3 P36888 1/20 0.43
HPGD P15428 4/20 0.40
PDE4B Q07343 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.39
ABCB1 P08183 1/20 0.39
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319882 0.86 GAA (0.68) GAATSHRLIG1KDM4EFLT3
SCHEMBL15921513 0.85 KDM4E (0.50) GAATSHRKDM4EHPGDALDH1A1
SCHEMBL15921820 0.84 LIG1 (0.51) GAATSHRLIG1KDM4EFLT3
SCHEMBL11368844 0.83 GAA (0.78) GAATSHRLIG1KDM4EFLT3
SCHEMBL8164464 0.82 GAA (0.53) GAATSHRLIG1KDM4EFLT3
SCHEMBL20471940 0.82 GAA (0.58) GAATSHRLIG1KDM4EFLT3
SCHEMBL20471985 0.82 TSHR (0.55) GAATSHRLIG1KDM4EFLT3
SCHEMBL15423768 0.81 KCNMA1 (0.48) TSHRKDM4EHPGDNPC1ALDH1A1
SCHEMBL11062415 0.80 ABCB1 (0.54) GAATSHRLIG1KDM4EALDH1A1
SCHEMBL1428 0.78 LIG1 (0.67) GAATSHRLIG1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2951180-B1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME (US) 2018-05-02 EP disclosed
US-9540377-B2 2,6,7,8 substituted purines as HDM2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-01-10 US disclosed
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-10 US disclosed
EP-2951180-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-12-09 EP disclosed
WO-2014120748-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353553-A1 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS DDX21, DPYD, NSUN2 GAA 3490/4885TSHR 4844/4885LIG1 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.